Hangzhou Alltest Biotech (688606) 东吴证券·2024-10-31 22:30Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company has shown significant improvement in its operational performance, with Q3 2024 revenue reaching 222 million yuan, a year-on-year increase of 28.72%, and net profit attributable to shareholders of 74 million yuan, up 142.39% year-on-year [2] - The company focuses on the POCT (Point of Care Testing) market and has established a strong international presence, particularly in Europe and the United States, with products in infectious disease testing, drug abuse testing, and women's health [3] - The company has set ambitious revenue targets for 2024-2026, aiming for 850 million to 1.26 billion yuan, with a compound annual growth rate of 18.6% [3] Financial Performance Summary - For Q3 2024, the company reported a total revenue of 222 million yuan, with a gross profit margin increase of 44.50% compared to the same period last year [2] - The company’s total revenue for the first three quarters of 2024 was 618 million yuan, reflecting a year-on-year growth of 10.37% [2] - The forecast for net profit attributable to shareholders for 2024-2026 is adjusted to 246 million, 309 million, and 394 million yuan respectively, with corresponding EPS of 3.10, 3.89, and 4.98 yuan [4]